Illumina (NASDAQ:ILMN – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 5.300-5.400 for the period, compared to the consensus estimate of 5.230. The company issued revenue guidance of $4.6 billion-$4.6 billion, compared to the consensus revenue estimate of $4.6 billion.
Illumina Trading Up 5.3%
Shares of NASDAQ:ILMN traded up $10.27 during mid-day trading on Thursday, reaching $205.09. The stock had a trading volume of 2,763,077 shares, compared to its average volume of 1,887,874. The firm has a 50 day simple moving average of $174.28 and a two-hundred day simple moving average of $146.38. Illumina has a twelve month low of $88.00 and a twelve month high of $205.47. The firm has a market cap of $31.03 billion, a PE ratio of 37.29, a price-to-earnings-growth ratio of 2.85 and a beta of 1.47. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.
Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts predict that Illumina will post 5.22 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Analysis on Illumina
Insider Activity
In other news, CAO Scott D. Ericksen sold 1,500 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the transaction, the chief accounting officer directly owned 14,946 shares of the company’s stock, valued at $2,243,394.60. This represents a 9.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is currently owned by insiders.
Trending Headlines about Illumina
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Q2 earnings beat expectations: Illumina reported $1.16 billion in revenue, up approximately 9.5% year over year and ahead of the $1.13 billion consensus estimate. GAAP diluted EPS was $1.35, while non-GAAP diluted EPS was $1.31, exceeding analysts’ $1.23 forecast. Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
- Positive Sentiment: Improved operating performance: Gross profit rose 10.8% to $770 million, and operating profit increased 14.5% to $245 million. GAAP operating margin was 21.1%, supported by revenue growth and improved efficiency. The company also generated $201 million in operating cash flow and ended the quarter with $1.04 billion in cash.
- Positive Sentiment: Raised earnings outlook and strategic partnership: Illumina set fiscal 2026 EPS guidance at $5.30-$5.40, above the $5.23 analyst consensus, while revenue guidance was broadly in line with expectations. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, potentially strengthening Illumina’s role in genomic data and AI-driven drug discovery. Eli Lilly Joins Illumina’s Billion Cell Atlas
- Neutral Sentiment: Mixed investor signals: Institutional investors had mixed positioning, with some large funds adding shares and others reducing holdings. Recent analyst targets have a median of $185, below the stock’s latest trading level, suggesting valuation and expectations may limit additional upside.
- Negative Sentiment: Insider selling and lower net income: Insiders recorded 41 sales versus one purchase over the past six months, including substantial selling by Keith Meister. Net income attributable to common shareholders declined 11.9% year over year to $207 million, despite stronger revenue and operating profit.
Institutional Trading of Illumina
A number of hedge funds and other institutional investors have recently made changes to their positions in ILMN. Quarry LP acquired a new stake in Illumina in the 3rd quarter valued at $32,000. Brown Brothers Harriman & Co. grew its position in shares of Illumina by 975.6% in the 4th quarter. Brown Brothers Harriman & Co. now owns 441 shares of the life sciences company’s stock valued at $58,000 after acquiring an additional 400 shares during the period. Itau Unibanco Holding S.A. grew its position in shares of Illumina by 93.1% in the 4th quarter. Itau Unibanco Holding S.A. now owns 556 shares of the life sciences company’s stock valued at $73,000 after acquiring an additional 268 shares during the period. Advisory Services Network LLC acquired a new position in shares of Illumina during the 3rd quarter worth about $102,000. Finally, Headlands Technologies LLC acquired a new position in shares of Illumina during the 2nd quarter worth about $165,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.
Illumina Company Profile
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Stories
- Five stocks we like better than Illumina
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
